AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds

AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds

AstraZeneca’s deal with CSPC Pharmaceutical Group includes a Phase 1-ready obesity drug that hits the same targets as Eli Lilly’s obesity drug Zepbound, but with monthly dosing. The new collaboration builds on an existing drug R&D relationship between the two companies. The post AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds appeared first on MedCity News.

AstraZeneca looks to China for obesity drug candidates

Today's biotech news covers TrumpRx launch delayed, Sanofi shelving mRNA flu shots, and the high stakes for Huntington's patients.

AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal

AstraZeneca deepens ties with China, pledging $15bn in investment and signing a big $18.5bn alliance with CSPC Pharma for obesity and diabetes drugs.

AstraZeneca secures tie-up with Chinese firm for weight loss drugs

The deal includes giving AstraZeneca access to the exclusive global rights, outside China, to CSPC’s once-a-month weight management jabs.

AstraZeneca China Obesity Drug Deal Worth Up to $18.5B

Biotechnology powerhouse AstraZeneca has inked a landmark licensing agreement with China’s CSPC Pharmaceutical Group Ltd., potentially worth $18.5 billion, aimed at developing and commercializing weight-loss and type 2 diabetes therapies globally, the companies announced Friday. The deal marks a significant move in Western pharmaceutical investment in China and highlights the growing global race for obesity treatments. Deal Terms and Milestones …